Disc Medicine shows hope for people with sunlight sensitivity after a successful study.

Oct 19, 2026, 12:41 PM ETResultsRead the original at Benzinga

Good for IRON

Disc Medicine's bitopertin met every Phase 3 goal and helped patients spend more time in light without pain, supporting its path toward approval. Dizziness affected 50% of treated patients, but cases were generally mild to moderate, and no event exceeded Grade 3.

IRON · Disc Medicine Inc.

AI read · Good for IRON

The AI's read

These results give Disc Medicine a stronger basis to seek U.S. approval and could help people who cannot tolerate sunlight. Dizziness affected 50% of treated patients, but cases were generally mild to moderate, and none exceeded Grade 3. Approval is still pending: the company plans to file by year-end, with an FDA decision expected by mid-2027.

Get alerts for IRON

Follow Disc Medicine Inc. (IRON) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IRON

Free on the App Store and Google Play, or on the web.